JBM (Healthcare) Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St · 07/04 22:08

JBM (Healthcare) (HKG:2161) Full Year 2025 Results

Key Financial Results

  • Revenue: HK$782.3m (up 21% from FY 2024).
  • Net income: HK$197.3m (up 51% from FY 2024).
  • Profit margin: 25% (up from 20% in FY 2024). The increase in margin was driven by higher revenue.
  • EPS: HK$0.22 (up from HK$0.15 in FY 2024).
earnings-and-revenue-growth
SEHK:2161 Earnings and Revenue Growth July 4th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

JBM (Healthcare) EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 20%.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 5.2% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for JBM (Healthcare) you should know about.